CytoMed Therapeutics announces Chairman's Letter to the Company's shareholders

Core Insights - CytoMed Therapeutics Limited is focusing on the development of affordable GMP-grade immune cells for patients with cancer and autoimmune diseases, leveraging Asia's low-cost infrastructure and talent [3][4] - The company has transitioned to a clinical stage biopharma with the initiation of the ANGELICA trial, which is the first-in-human CAR T trial using donor-derived allogeneic gamma delta T cells [4][10] - CytoMed has made strategic acquisitions and partnerships to enhance its capabilities and expand into new markets, including the acquisition of a licensed cord blood bank and collaborations in China and India [5][6] Company Developments - The ANGELICA trial commenced in November 2024, with a small patient recruitment target of no more than 20 late-stage cancer patients, supported by a significant grant from the National Medical Research Council of Singapore [4] - The acquisition of a cord blood bank for approximately US$ 450,000 aims to provide raw materials for new cord blood-derived therapeutics, with plans to spin off this subsidiary in the future [5] - CytoMed is establishing a presence in New York to enhance its profile in the US market and explore opportunities for mergers and acquisitions [10] Strategic Direction - The company plans to implement revenue-generating methods for late-stage patients on a compassionate basis, including investments in clinics and partnerships with hospitals [11] - CytoMed is working towards submitting a US FDA IND for its allogeneic gamma delta T cells and aims for initial clinical readout of the ANGELICA trial by mid-2025 [10] - The company is also involved in an international AI project to utilize its gamma delta T cells for treating infectious diseases in developing countries [9]